CordenPharma has had its near-term greenhouse gas (GHG) emission reduction targets approved by the Science-Based Targets initiative (SBTi).
This follows the company's two year carbon footprint measurement process, which resulted in the submission of targets to the group in November 2024.
The approved, near-term science-based targets include:
- Reducing absolute scope 1 and 2 GHG emissions by 55% by 2033
- Ensuring that at least 72% of its suppliers will have science-based targets by 2029 (includes purchased goods and services, capital goods, fuel and energy-related activities, upstream transportataion/distribution and operational waste)
The SBTi was set up to provide companies with a clear and science-backed framework to reduce emissions and support global efforts to limit the impacts of climate change.
By working to meet these targets, CordenPharma will reinforce its efforts to operate sustainably, supporting pharma and biotech innovators while also contributing to the health of the planet.
In the future, CordenPharma hope to transition to 100% renewable electricity across all global facilities.
The company will also invest in the energy efficiency of its production processes and facilities, reducing emissions and resource consumption.
CordenPharma will also collaborate with its suppliers, customers and stakeholers to encourage the implementation of carbon reduction strategies.
“Our sustainability teams across all global sites have worked with passion and diligence to develop robust emission reduction targets," noted William Cashin, Chief Quality & Compliance Officer at CordenPharma.
"With the full support of our shareholders Astorg, we are united in our ambition to lead in climate action and provide greater transparency to our customers, employees, and stakeholders. This validation strengthens our role as a trusted CDMO partner—one that prioritises environmental responsibility alongside service excellence," he concluded.